A recent study found that the AstraZeneca antibody cocktail treatment (AZD442) did not have a significant effect on inhibiting Covid-19. It had an impact of only 33 percent, which was negligible. And it was failed in the trials. Above 18 years old have been used for these trials.
When compared with placebo treatment, AZD 442 induced only 33% in preventing the development of symptoms in the covid patients. AstraZeneca Executive Vice President Mene Pangalos said the drug had failed to reach a primary endpoint.
AstraZeneca’s idea is to reduce the severity of the disease by treating this in advance in people with corona infection. However, now it has failed to make much of an impact. Antibody therapy is a combination of certain drugs. It stimulates the body’s antibodies to fight covid infection.
Monoclonal antibody therapy was jointly developed by rivals Regeneron Pharmaceuticals Inc. (REGN.O) and Eli Lilly & Co. (LLY, N). The permission has been granted to provide this treatment to corona patients in the United States. It is also licensed by the European Medicines Agency (EMA). There is also American support for the manufacture of this drug. AstraZeneca announced that it had reached an agreement to supply the US with five million doses of AZD 7442, in March of this year.
However, the results of a recent study suggest that this could be a major setback for AstraZeneca. It says more studies will shed more light on the drug.